Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

BIOMARIN PHARMACEUTICAL INC Form 4 November 14, 2016

November 12	+, 2010									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION						OMB APPROVAL				
	UNITED		RITIES A shington,			NGE C	OMMISSION	OMB Number:	3235-0287	
Check thi if no long	er.							Expires:	January 31, 2005	
subject to Section 1	6. SIAIEM	IENT OF CHAN	F CHANGES IN BENEFICIAL OWNI SECURITIES				NERSHIP OF	Estimated a burden hour	verage rs per	
Form 4 or Form 5 obligations may continue.response0See Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19400								0.5		
(Print or Type F	Responses)									
			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL				5. Relationship of Reporting Person(s) to Issuer			
		INC [BMRN]				(Check all applicable)				
(Last)		Irst) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)				X Director 10% Owner Officer (give title Other (specify below) below)				
C/O BIOMA PHARMAC DIGITAL D	EUTICAL INC.,	11/09/2 105	2016				below)	below)		
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				1		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
NOVATO,	CA 94949						Form filed by M Person	ore than One Re	porting	
(City)	(State)	(Zip) Tab	le I - Non-D	Derivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	11/09/2016(1)	11/09/2016	М	7,500	А	\$ 17.33	21,360	D		
Common Stock	11/09/2016(1)	11/09/2016	S	7,500	D	\$ 95 (2)	13,860	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy) Common Stock	\$ 17.33	11/09/2016 <u>(1)</u>	11/09/2016	М	7,500	12/07/2007 <u>(3)</u>	06/06/2017	Common Stock	7,500

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director 10% Owner Offic		Officer	Other		
LAWLIS V BRYAN C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	Х					
Signatures						
/s/ Laura Randall Woodhead, Attorney-in-Fact	11/14	4/2016				
<u>**</u> Signature of Reporting Person	D	ate				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a 10b5-1 trading plan executed on June 6, 2016.
- (2) All shares were sold at the same price.
- (3) Original option grant vests 6/48ths on December 7, 2007, and 1/48th on the 7th day of every month thereafter
- (4) Reflects the number of stock options that remain outstanding from this specific stock grant following the reported transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.